1. Home
  2. OFS vs ACET Comparison

OFS vs ACET Comparison

Compare OFS & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • OFS
  • ACET
  • Stock Information
  • Founded
  • OFS 2001
  • ACET 1947
  • Country
  • OFS United States
  • ACET United States
  • Employees
  • OFS N/A
  • ACET N/A
  • Industry
  • OFS Finance/Investors Services
  • ACET Biotechnology: Pharmaceutical Preparations
  • Sector
  • OFS Finance
  • ACET Health Care
  • Exchange
  • OFS Nasdaq
  • ACET Nasdaq
  • Market Cap
  • OFS 109.9M
  • ACET 109.6M
  • IPO Year
  • OFS 2012
  • ACET N/A
  • Fundamental
  • Price
  • OFS $8.02
  • ACET $0.95
  • Analyst Decision
  • OFS
  • ACET Strong Buy
  • Analyst Count
  • OFS 0
  • ACET 4
  • Target Price
  • OFS N/A
  • ACET $5.67
  • AVG Volume (30 Days)
  • OFS 46.0K
  • ACET 466.3K
  • Earning Date
  • OFS 10-31-2024
  • ACET 11-06-2024
  • Dividend Yield
  • OFS 16.96%
  • ACET N/A
  • EPS Growth
  • OFS N/A
  • ACET N/A
  • EPS
  • OFS N/A
  • ACET N/A
  • Revenue
  • OFS $49,799,000.00
  • ACET N/A
  • Revenue This Year
  • OFS N/A
  • ACET N/A
  • Revenue Next Year
  • OFS N/A
  • ACET N/A
  • P/E Ratio
  • OFS N/A
  • ACET N/A
  • Revenue Growth
  • OFS N/A
  • ACET N/A
  • 52 Week Low
  • OFS $7.75
  • ACET $0.93
  • 52 Week High
  • OFS $12.41
  • ACET $3.77
  • Technical
  • Relative Strength Index (RSI)
  • OFS 43.72
  • ACET 20.89
  • Support Level
  • OFS $7.99
  • ACET $1.20
  • Resistance Level
  • OFS $8.09
  • ACET $1.40
  • Average True Range (ATR)
  • OFS 0.14
  • ACET 0.10
  • MACD
  • OFS 0.00
  • ACET -0.04
  • Stochastic Oscillator
  • OFS 42.00
  • ACET 3.25

About OFS OFS Capital Corporation

OFS Capital Corp is an externally managed, closed-end, non-diversified management investment company. Its business objective is to generate current income and capital appreciation by investing in middle-market companies in the United States. The company focuses on investments in senior secured loans, including first lien, second lien, and unitranche loans, as well as subordinated loans and, to a lesser extent, warrants, and other equity securities.

About ACET Adicet Bio Inc.

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its lead product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its lead preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.

Share on Social Networks: